- · 《临床药物治疗杂志》编[10/30]
- · 《临床药物治疗杂志》杂[10/30]
- · 《临床药物治疗杂志》杂[10/30]
- · 《临床药物治疗杂志》期[10/30]
- · 《临床药物治疗杂志》数[10/30]
- · 《临床药物治疗杂志》投[10/30]
- · 临床药物治疗杂志版面费[10/30]
年系统性硬化症和大流行世界硬皮病基金会对患(6)
作者:网站采编关键词:
摘要:[23]AVOUAC J,AIRó P,CARLIER N,et al.Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab[J].Ann Rheum Dis,2020:annrheumdis-annrheu20
[23]AVOUAC J,AIRó P,CARLIER N,et al.Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab[J].Ann Rheum Dis,2020:annrheumdis-annrheu2020-.DOI:10.1136/annrheumd is-2020-.
[24]NOJOMI M,YASSIN Z,KEYVANI H,et al.Effect of Arbidol(Umifenovir) on COVID-19:a randomized controlled trial[J].BMC Infect Dis,2020,20(1):954.DOI:10.1186/s-020-05698-w.
[25]SALLARD E,LESCURE F X,YAZDANPANAH Y,et al.Type 1 interferons as a potential treatment against COVID-19[J].Antiviral Res,2020,178:.DOI:10.1016/.
[26]WALZ L,COHEN A J,REBAZA A P,et al.JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients:a systematic review and meta-analysis[J].BMC Infect Dis,2021,21(1):47.DOI:10.1186/s-020-05730-z.
[27]DAVOUDI-MONFARED E,RAHMANI H,KHALILI H,et al.A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19[J].Antimicrob Agents Chemother,2020,64(9):e01061-01020.DOI:10.1128/.
[28]RAHMANI H,DAVOUDI-MONFARED E,NOURIAN A,et al.Interferon β-1b in treatment of severe COVID-19:a randomized clinical trial[J].Int Immunopharmacol,2020,88:.DOI:10.1016/.
[29]DELANEY T A,MOREHOUSE C,BROHAWN P Z,et al.Type I IFNs regulate inflammation,vasculopathy,and fibrosis in chronic cutaneous graft-versus-host disease[J].J Immunol,2016,197(1):42-50.DOI:10.4049/jimmunol..
[30]SAVARINO A,DI TRANI L,DONATELLI I,et al.New insights into the antiviral effects of chloroquine[J].Lancet Infect Dis,2006,6(2):67-69.DOI:10.1016/S1473-3099(06)-9.
[31]WANG M L,CAO R Y,ZHANG L K,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV) in vitro[J].Cell Res,2020,30(3):269-271.DOI:10.1038/s-020-0282-0.
[32]JANG C H,CHOI J H,BYUN M S,et al.Chloroquine inhibits production of TNF-alpha,IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes[J].Rheumatology(Oxford),2006,45(6):703-710.DOI:10.1093/rheumatology/kei282.
[33]EKTORP E.Death threats after a trial on chloroquine for COVID-19[J].Lancet Infect Dis,2020,20(6):661.DOI:10.1016/s1473-3099(20)-2.
[34]SELF W H,SEMLER M W,LEITHER L M,et al.Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19:a randomized clinical trial[J].JAMA,2020,324(21):2165-2176.DOI:10.1001/.
[35]GROUP R C,HORBY P,MAFHAM M,et al.Effect of hydroxychloroquine in hospitalized patients with covid-19[J].N Engl J Med,2020,383(21):2030-2040.DOI:10.1056/NEJMoa.
[36]XU X L,HAN M F,LI T T,et al.Effective treatment of severe COVID-19 patients with tocilizumab[J].Proc Natl Acad Sci USA,2020,117(20):-.DOI:10.1073/pnas..
[37]COPAESCU A,SMIBERT O,GIBSON A,et al.The role of IL-6 and other mediators in the cytokine storm associated with SARSCoV-2 infection[J].J Allergy Clin Immunol,2020,146(3):.DOI:10.1016/.
[38]CHEN G,WU D,GUO W,et al.Clinical and immunological features of severe and moderate coronavirus disease 2019[J].J Clin Invest,2020,130(5):2620-2629.DOI:10.1172/JCI.
[39]JIN Y H,CAI L,CHENG Z S,et al.A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)[J].Mil Med Res,2020,7(1):4.DOI:10.1186/s-020-0233-6.
[40]LESCOAT A,LELONG M,JELJELI M,et al.Combined antifibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo:perspectives for sclerodermaassociated interstitial lung disease[J].Biochem Pharmacol,2020,178:.DOI:10.1016/.
[41]RICARD L,JACHIET V,MALARD F,et al.Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib[J].Ann Rheum Dis,2019,78(4):539-550.DOI:10.1136/annrheumdis-2018-.
[42]GOZZETTI A,CAPOCHIANI E,BOCCHIA M.The janus kinase 1/2 inhibitor ruxolitinib in COVID-19[J].Leukemia,2020,34(10):2815-2816.DOI:10.1038/s-020-01038-8.
[43]REYNOLDS H R,ADHIKARI S,PULGARIN C,et al.Reninangiotensin-aldosterone system inhibitors and risk of covid-19[J].N Engl J Med,2020,382(25):2441-2448.DOI:10.1056/NEJMoa.
[44]ZHANG G Y,WU Y,XU R,et al.Effects of renin-angiotensinaldosterone system inhibitors on disease severity and mortality in patients with COVID-19:a meta-analysis[J].J Med Virol,2020.DOI:10.1002/jmv..
文章来源:《临床药物治疗杂志》 网址: http://www.lcywzlzz.cn/qikandaodu/2021/0622/1182.html